ABSTRACT

Introduction: Lung cancer is the leading cause of cancer death worldwide, showing an increase in women and non-smokers in the last decade. Progress in the diagnostic-therapeutic approach has been achieved thanks to the knowledge of tumor heterogeneity and molecular analysis. Material and methods: The base of patients with lung cancer was analyzed from January 2013 to June 2018, with registration of sociodemographic, clinical and molecular profile variables. Results expressed through measures of central tendency and crude odd ratio was estimated for EGFR mutation and exposure antecedent and its statistical significance by Fisher’s exact test. Results: A cohort analyzed from January 2013 to June 2018 with 751 patients. The average age was 62.2 years, 53% (n = 398) were female, 51.8% (n = 389) were never smokers. The most common symptoms were cough in 87.1% and dyspnea in 74.4%. The bronchoscopic procedure was the preferred diagnostic method. Clinical stage IV was the most frequently reported. EGFR was positive in 38.19% of NSCLC. Conclusion: The clinical-epidemiological situation of the INER resembles global statistics in both diagnosis and personalized treatments.

KEYWORDS

Lung cancer, non-smoking, prognosis.

REFERENCES

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96. doi: 10.3322/ CA.2007.0010.

2. Arrieta O, Guzmán-de Alba E, Alba-López LF, et al. Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Rev Invest Clin 2013;65(Supl. 1):s5-s84.

3. Franco-Marina F, Villalba-Caloca J. La epidemia de cáncer pulmonar en México. Rev Inst Nal Enf Resp Mex 2001;14(4):207-214.

4. Campos-Parra AD, Cruz-Rico G, Arrieta O. Genotipificación en cáncer de pulmón de células no pequeñas. GAMO 2012;11(1):35-44.

5. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321(7257):323-329. doi: 10.1136/bmj.321.7257.323.

6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90. doi: 10.3322/ caac.20107.

7. Encuesta Nacional de Adicciones. [Fecha de acceso 12 de junio de 2019]. Accesible en: http://www.conadic.salud.gob.mx/pdfs/ena08/ ENA08_NACIONAL.pdf

8. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009;54(1):12-27. doi: 10.1111/j.1365- 2559.2008.03176.x.

9. Wallace WA. The challenge of classifying poorly differentiated tumours in the lung. Histopathology 2009;54(1):28-42. doi: 10.1111/j.1365- 2559.2008.03181.x.

10. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315(3):971-979. doi: 10.1124/ jpet.105.084145.

11. Pérez M, Murillo R, Pinzón C, Hernández G. Costos de la atención médica del cáncer de pulmón, la EPOC y el IAM atribuibles al consumo de tabaco en Colombia (proyecto multicéntrico de la OPS). Rev Colomb Cancerol 2007;11(4):241-249.

12. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38(1):17-23.

13. Campos-Parra AD, Cruz-Rico G, Arrieta O. Personalized treatment in non-small cell lung cancer. Rev Inv Clin 2012;64(4):377-386.

14. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008;20(2):162-175. doi: 10.1097/ CCO.0b013e3282f335a3.

15. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359(13):1367-1380. doi: 10.1056/NEJMra0802714.

16. Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15(4):504-535. doi: 10.6004/ jnccn.2017.0050.

17. De Koning H, Van C, Ten K. Effects of volume CT lung cancer screening: Mortality results of the NELSON randomized-controlled population based trial. 2018 World Conference on Lung Cancer. Abstract PL02.05. Presented September 25, 2018. Chicago, Illinois, EUA.

18. Guibert N, Mazieres J, Marquette CH, Rouviere D, Didier A, Hermant C. Integration of interventional bronchoscopy in the management of lung cancer. Eur Respir Rev 2015;24(137):378-391. doi: 10.1183/16000617.00010014.